NEUROCRINE BIOSCIENCES INC Deferred Tax Assets, Deferred Income
NEUROCRINE BIOSCIENCES INC (NBIX) had Deferred Tax Assets, Deferred Income of $2.80 million as of 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2018-02-13
- 2017-12-31: Deferred Tax Assets, Deferred Income $2.80M.
- 2016-12-31: Deferred Tax Assets, Deferred Income $4.30M.
- 2015-12-31: Deferred Tax Assets, Deferred Income $4.30M.
- 2014-12-31: Deferred Tax Assets, Deferred Income $800.00K.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2017-12-31 | $2.80M 10-K · filed 2018-02-13 |
| 2016-12-31 | $4.30M 10-K · filed 2018-02-13 |
| 2015-12-31 | $4.30M 10-K · filed 2017-02-14 |
| 2014-12-31 | $800.00K 10-K · filed 2016-02-11 |
| 2013-12-31 | $800.00K 10-K · filed 2015-02-09 |
| 2012-12-31 | $2.00M 10-K · filed 2014-02-11 |
| 2011-12-31 | $16.00M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |